UCB, a global biopharmaceutical company, has entered into a definitive agreement under which it would acquire Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system, including it lead asset NRTX-1001. Building on UCB’s heritage in epilepsy and its ambition to deliver differentiated solutions to patients with unmet needs, this acquisition marks a strategic expansion into regenerati...